New therapies, new directions: Advances in the systemic treatment of metastatic colorectal cancer

Lancet Oncology

Volumn 2, Issue 5, 2001, Pages 290-297

  Holen, Kyle D ^a   Saltz, Leonard B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 UFT PROTOCOL; 1-UFT PROTOCOL; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX; QUINAZOLINE DERIVATIVE; RALTITREXED; TEGAFUR; THIOPHENE DERIVATIVE; TRIMETREXATE; URACIL;

COLORECTAL TUMOR; FORECASTING; HUMAN; METASTASIS; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; FORECASTING; HUMANS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES; TEGAFUR; THIOPHENES; TRIMETREXATE; URACIL;

EID: 0035352412     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00324-7     Document Type: Review

References (53)

1. Scheithauer W., Rosen H., Kornek G.V., et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 306:1993;752-755.
2. Cunningham D., Pyrhonen S., James R., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 352:1998;1413-1418.
3. Doroshow J.H., Multhauf P., Leong L., et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol. 8:1990;491-501.
4. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol. 10:1992;896-903.
5. Poon M.A., O'Connell M., Wieand H.S., et al. Biochemical modulation of fluorouracil with leucovorin. Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol. 9:1991;1967-1972.
6. Buroker T.R., O'Connell M.J., Wieand H.D., et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol. 12:1994;14-20.
7. Leischman C.G., Fleming T.R., Muggia F.M., et al. Phase II study of fluorouracil and its modulation in advanced colorectal carcinoma: A prospective Southwest Oncology Group Study. J Clin Oncol. 13:1995;1303-1311.
8. Petrelli N., Douglas H.O., Herrera L., et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol. 7:1989;1419-1426.
9. Ardalan B., Chua C.L., Tian E., et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol. 9:1991;625-630.
10. Kohne C.H., Schoffski P., Wilke H., et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol. 16:1998;418-426.
11. De Gramont A., Bosset J.F., Milan C., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol. 15:1997;808-815.
12. Leichman C.G., Fleming T.R., Muggia F.M., et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol. 13:1995;1303-1311.
13. Kunimoto T., Nitta K., Kanaka T., et al. Antitumour activity of 7-ethyl-10 [4-(1-piperidino)-1-piperidino]-1-carbonyloxy-campotothecin, a novel water soluble derivative of camptothecin, against murine tumours. Cancer Res. 47:1987;5944-5947.
14. Sakata Y., Nakao I., Futatsuki K., et al. Phase II study of CPT-11, a new camptothecin derivative, in patients with advanced gastrointestinal cancer. J Jpn Soc Cancer Ther. 27:1992;2028-2035.
15. Shimada Y., Yoshino M., Wakui A., et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol. 11:1993;909-913.
16. Rothenberg M.L., Kuhn J.G., Burris H.A., et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 11:1993;2194-2204.
17. Rougier P., Bugat R., Douillard J.Y., et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 15:1997;251-260.
18. Rougier P., Van Cutsem E., Bajetta E., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 352:1998;1407-1412.
19. Conti J.A., Kemeny N.E., Saltz L.B., et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol. 14:1996;709-715.
20. Saltz L.B., Kanowitz J., Kemeny N., et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumours. J Clin Oncol. 14:1996;2959-2967.
21. Vanhoefer U., Harstrick A., Kohne C., et al. Phase I study of weekly schedule of irinotecan, high-dose leucovorin, and infusion flourouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol. 17:1999;907-913.
22. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet. 355:2000;1041-1047.
23. Saltz L., Cox J., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Eng J Med. 343:2000;905-914.
24. Saltz L., Douillard J., Pirotta N., et al. Proc Am Soc Clin Oncol. 19:2000;938a. (abstr).
25. Extra J.M., Espie M., Calvo F., et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 25:1990;299-303.
26. Caussanel J.P., Levi F., Brienza S., et al. Phase I trial of 5-day continuous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst. 82:1990;1046-1050.
27. Machover D., Dias-Rubio E., de Gramont A., et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Annals Oncol. 7:1996;95-98.
28. Levi F., Perpoint B., Garufi C., et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer. 29A:1993;1280-1284.
29. Levi F., Misset J.L., Brienza S., et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumour effectiveness against metastatic colorectal cancer. Cancer. 69:1992;893-900.
30. Bertheault-Cvitkovic F., Jami A., Ithzaki M., et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol. 14:1996;2950-2958.
31. de Gramont A., Vignoud J., Tournigand C., et al. Oxaliplatin with high-dose leucovorin and 5-flourouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 33:1997;214-219.
32. de Gramont A., Figer A., Seymour M., et al. Leucovorin and flourouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 18:2000;2938-2947.
33. Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicentre randomized trial of oxaliplatin added to chronomodulated flourouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Onc. 18:2000;136-147.
34. Pazdur R., Douillard J., Skillings J.R., et al. Proc Am Soc Clin Oncol. 18:1999;1009. (abstr).
35. Carmichael J., Popiela T., Radstone D., et al. Proc Am Soc Clin Oncol. 18:1999;1015. (abstr).
36. Twelves C., Harper P., van Cutsem E., et al. Proc Am Soc Clin Oncol. 18:1999;1010. (abstr).
37. Cox J., Pazdur R., Thibault A., et al. Proc Am Soc Clin Oncol. 18:1999;1016. (abstr).
38. Goldberg R., Kugler J., Mahoney M., et al. A phase II trial of 7 days of oral 776C85 plus 5 days of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer (M-CRC): a North Central Cancer Treatment Group study. Proc Am Soc Clin Oncol. 19:2000;950. (abstr).
39. Mani S., Beck T., Chevlen E., et al. A phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol. 19:2000;281a. (abstr).
40. Evans S., Su Y., Danskin J., et al. Activity profile of trimetrexate (TMTX) and 5-fluorouracil (5-FU) in human tumours. Proc Am Soc Clin Oncol. 18:1999;740a. (abstr).
41. Blanke C., Kasimis B., Schein P., et al. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol. 15:1997;915-920.
42. Conti J., Kemeny N., Seiter K., et al. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol. 12:1994;695-700.
43. Cuningham D., Zalcberg J., Rath U., et al. Final results of a randomized trial comparing "tomudex" (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol. 7:1996;961-965.
44. Pazdur R., Vincent M. Raltitrexed versus 5-fluorouracil and leucovorin in patients with advanced colorectal cancer: results of a randomized multicenter North American trial. Proc Am Soc Clin Oncol. 16:1997;801. (abstr).
45. Harper P, on behalf of the tomudex study group. Advanced colorectal cancer: results from the latest raltitrexed comparative study. Proc Am Soc Clin Oncol 1997; 16: 228a (abstr).
46. Maughan T.S., James R.D., Kerr D., et al. Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (de Gramont, Lokich, and raltitrexed) in metastatic colorectal cancer. Proc Am Soc Clin Oncol. 18:1999;1007. (abstr).
47. Dragney K., Schwartz G., Bertino J., et al. Interim results of a phase I trial suggest that tomudex (raltitrexed) may act synergistically with 5-fluorouracil (5-FU) in patients with advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol. 17:1998;868a. (abstr).
48. Schwartz G.K., Harstrick A., Gonzalez Baron M. Raltitrexed (tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials. Eur J Cancer. 35:1999;S9-13.
49. Fizazi K., Ducreux M., Ruffie P., et al. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin inpatients with advanced cancer. J Clin Oncol. 18:2000;2293-2300.
50. Douillard J., Michel P., Gamelin E., et al. Raltitrexed plus oxaliplatin: an active combination for first-line chemotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol. 19:2000;971. (abstr).
51. Garcia M., Gilles V., Louvet C., et al. Bi-weekly irinotecan combined with raltitrexed treatment in heavily pre-treated patients with advanced colorectal cancer: a feasibility study. Proc Am Soc Clin Oncol. 19:2000;987(abstr.
52. Ford H.E., Cunningham D., Ross P.J., et al. Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma. British J Cancer. 83:2000;146-152.
53. Nobile M.T., Gozza A., Heouaine A., et al. Irinotecan and raltitrexed in advanced colorectal cancer: a phase II study. Proc Am Soc Clin Oncol. 19:2000;1220. (abstr).